Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
1990-3-5
|
pubmed:abstractText |
Ten patients with relapsing high grade brain gliomas and one patient with low grade glioma were studied with a monoclonal antibody (H17E2) against placental alkaline phosphatase. In addition 2 patients with relapsing high grade glioma were studied with a non specific antibody (4D513/2118). 1 mCi of Iodine-131-labelled H17E2 was administered intracarotidly (i.c.) in two, and intravenously (i.v.) in 9 patients. Immunoscintigrams were taken at 0, 2, 24, 48 and 72 hours. Radioactivity was monitored in blood and urine. Tumour/non-tumour ratios were estimated (max. 2.45). All high grade gliomas receiving specific antibody irrespective of the route of administration, gave a positive immunoscintigraphic pattern, increasing in intensity with time. Disappearance of radioactivity in blood was biexpontential with a long component over 30 hours. Urinary excretion of radioactivity ranged from 3.7-21.7% of administered dose/day. The patient with low grade glioma and the patients receiving non specific monoclonal antibody showed a negative pattern, a fast blood clearance and a high urinary excretion. We conclude that a) Iodine-131 labelled H17E2 proved to be stable in vivo and produced satisfactory tumour localisation and b) i.v. route was as good as i.c.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:issn |
0393-6155
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
4
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
135-41
|
pubmed:dateRevised |
2004-11-17
|
pubmed:meshHeading |
pubmed-meshheading:2614081-Alkaline Phosphatase,
pubmed-meshheading:2614081-Antibodies, Monoclonal,
pubmed-meshheading:2614081-Brain Neoplasms,
pubmed-meshheading:2614081-Glioma,
pubmed-meshheading:2614081-Humans,
pubmed-meshheading:2614081-Iodine Radioisotopes,
pubmed-meshheading:2614081-Kinetics,
pubmed-meshheading:2614081-Tumor Markers, Biological
|
pubmed:articleTitle |
A preliminary study of brain gliomas with H17E2 monoclonal antibody: immunoscintigraphy and pharmacokinetics.
|
pubmed:affiliation |
Agii Anargiri Cancer Hospital, Athens, Greece.
|
pubmed:publicationType |
Journal Article
|